Table 3.
MIF and percentage of inflammatory (TNF-α, IL-1α and IL-6) and anti-inflammatory (IL-10) cytokine-producing CD14− cells from controls and CFS/FMS patients cultured for 6 h in the presence of polymyxin B. PBMC were cultured for 6 h with (stimulated) or without (ustimulated) human recombinant IFN-γ. Results, given as medians (means) and [25th and 75th percentiles], are the percentage of cytokine-producing CD14− cells (upper row) and MIF (lower row) in whole PBMC.
| Controls(n = 13) | CFS/FM(n = 15) | |||
|---|---|---|---|---|
| Cytokines | Unstimulated | Stimulated | Unstimulated | Stimulated |
| TNF-α | ||||
| %cells | 0·6 (0·6)[0·4–0·68]* | 0·8 (0·9)[0·62–1·14]** | 0·62 (0·6)[0·54–0·68] | 0·91 (0·93)[0·63–1·1] |
| MIF | 97 (103)[73–120] | 93 (92)[82–104] | 77 (88)[72–94] | 84 (83)[77–90] |
| IL-1α | ||||
| %cells | 0·0 (0·02)[0·0–0·06]* | 0·0 (0·06)[0·0–0·15]** | 0·01 (0·17)[0·0–0·08] | 0·01(0·33)[0·0–0·93] |
| MIF | 0·0 (41)[0·0–115] | 0·0 (56)[0·0–145] | 114 (103)[0·0–202] | 64 (102)[0·0–235] |
| IL-6 | ||||
| %cells | 0·08 (0·2)[0·0–0·38]* | 0·33 (0·33)[0·1–0·6]** | 0·02 (0·07)[0·0–0·08] | 0·01 (0·07)[0·0–0·11] |
| MIF | 111 (92)[0·0–140] | 117 (92)[50–135] | 84 (69)[0·0–127] | 40 (69)[0·0–137] |
| IL-10 | ||||
| %cells | 0·63 (0·74)[0·17–1·0]* | 0·45 (0·83)[0·16–1·32]** | 0·30 (1·0)[0·17–2·2] | 0·57 (1·7)[0·05–3·5] |
| MIF | 44 (46)[38–53] | 48 (46)[40–53] | 52 (50)[39–57] | 41 (47)[39–59] |
*
P > 0·05 comparing percentage of cells and MIF in the unstimulated normal group with the unstimulated CFS/FMS group.
**
P > 0·05 comparing percentage of cells and MIF in the hrIFN-γ-stimulated normal group with the hrIFN-γ-stimulated CFS/FMS group.